Mass spectrometry, Proteomics, Diabetes, Chemical Biology
Diabetes and its associated complications are becoming global public health problems and posing a serious challenge in disease management. Advanced Glycation End products (AGEs) are implicated in development of insulin resistance, as well as in pathogenesis of diabetic complications. In this context, we have developed methods to quantify plasma AGEs, identified risk factors for elevated plasma AGEs, discovered drug molecules that have the potential to be repositioned as glycation inhibitors, and identified the molecular mechanism for glycation induced formation of protease resistant proteins. The long-term goal is to identify diagnostic markers for various diabetic complications, identify drug targets and develop intervention strategies.